Proteasome inhibition in cancer: Development of PS-341

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 613-619

  Adams, J ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CELL PROTEIN; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 6; PROTEASOME INHIBITOR; UBIQUITIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; GENETIC TRANSCRIPTION; HUMAN; MYELOMA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW;

EID: 0035215395     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90034-X     Document Type: Article

References (42)

1. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
2. Proteasom inhibitors: A novel class of potent and effective antitumor agents
3. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome
4. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κb inhibition
5. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
6. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
7. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κb, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
8. The SCFβTRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro
9. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies
10. Dose dependent inhibition of 20S proteasome results in serum II-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341
11. Structure of 20S proteasome from yeast at 2.4 Å resolution
12. Crystal structure of the 20S proteasome from the archaeon T acidophilum at 3.4 A resolution
13. Catalytic mechanism of the 20S proteasome of thermoplasma acidophilum revealed by x-ray crystallography
14. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
15. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
16. Protease inhibitorinduced apoptosis: Accumulation of wt p53, p21WAF1/CIP 1, and induction of apoptosis are independent markers of proteasome inhibition
17. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-Lnorleucinal in platelet-derived growth factor-stimulated human fibroblasts
18. Detailed analysis of cell cycle kinetics upon proteasome inhibition
19. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67
20. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
21. How proteolysis drives the cell cycle
22. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
23. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bclx(L)
24. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
25. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
26. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis
27. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
28. Signal-induced degradation of IκB alpha requires site-specific ubiquitination
29. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP
30. Stimulationdependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway
31. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκB-α
32. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitinproteasome pathway
33. Siebenlist U: Activation of NF-κB requires proteolysis of the inhibitor IκB-α: Signal-induced phosphorylation of IκB-α alone does not release active NF-κB
34. Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo
35. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α
36. Proteasome inhibitor, PS-341, and its effect on tumor-bearing mice
37. TNF-α and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
38. NF-κB and chemoresistance: Potentiation of cancer chemotherapy via inhibition of NF-κB
39. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
40. Proteasome inhibition measurements: Clinical application
41. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints
42. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies